Navigation Links
ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences
Date:10/29/2010

EXTON, Pa., Oct. 29 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the Oppenheimer 21st Annual Healthcare Conference at 3:55 P.M. ET on Tuesday, November 2, 2010.  The conference is being held at the Waldorf=Astoria in New York City.

Charles Rowland, vice president and chief financial officer, of ViroPharma, will present at the Lazard Capital Markets 7th Annual Healthcare Conference at 1:45 P.M. ET on Wednesday, November 17, 2010.  The conference is being held at the St. Regis Hotel in New York City.

Mr. Rowland will also present at the 4th Annual Maxim Group Growth Conference at 9:30 A.M. ET on Thursday, November 18, 2010.  The conference is being held at the Grand Hyatt in New York City.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze™ (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
2. ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010
3. ViroPharma to Present at the Jefferies 2010 Global Healthcare Conference
4. ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
5. ViroPharma To Participate in Two September Healthcare Investor Conferences
6. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
7. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
8. ViroPharma to Participate in Two June Healthcare Investor Conferences
9. ViroPharma To Host Investor Day
10. ViroPharma to Participate in the Cowen and Company 30th Annual Healthcare Conference
11. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 26, 2016   Change Healthcare , ... network solutions and technology-enabled services designed to ... into a strategic channel partnership with SourceMed, ... solutions and revenue cycle management services that ... rehabilitation clinics to optimize revenue, operational efficiency ...
(Date:5/25/2016)... , May 25, 2016 According ... by Type (3D, 2D, 4D), by Therapeutic Area (Oncology, ... End User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast ... global Medical Animation Market for the forecast period of ... USD 301.3 Million by 2021 from USD 117.3 Million ...
(Date:5/25/2016)... May 25, 2016  Zymo Research Corp. announced ... new reference materials that help researchers obtain the ... to analyses. The rapid growth of the study ... to have standard methods to improve the reproducibility ... inherently exist at every step of the measurement ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... Southland Log Homes , designer and manufacturer ... barn kits, which can be found on its website at SouthlandLogHomes.com. , The designs ... and they highlight the craftsmanship of timber post and beam construction. The result ...
(Date:5/27/2016)... ... ... W.S. Badger Co. Inc ., the maker of certified organic and ... of the best small businesses for new dads by Fatherly, the digital lifestyle guide ... progressive benefits to new parents on the organization’s 2016 Best Places to Work ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, 2016 , ... ... or needing intervention to walk, the demand for a sustainable product to aid in ... this void and aid in the recovery of individuals with hemiplegia due to stroke. ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... readers, this installment is bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities ... within the industry, from leading advocates, associations and industry leaders such as Bioness. ...
(Date:5/27/2016)... ... May 27, 2016 , ... Beleza Medspa ... fat composition regulations. This is the first time that Coolsculpting is being used ... least every six months to ensure they meet the prescribed body-fat standard, measured by ...
Breaking Medicine News(10 mins):